DK3631017T3 - Fremgangsmåder til melanompåvisning - Google Patents

Fremgangsmåder til melanompåvisning Download PDF

Info

Publication number
DK3631017T3
DK3631017T3 DK18731615.3T DK18731615T DK3631017T3 DK 3631017 T3 DK3631017 T3 DK 3631017T3 DK 18731615 T DK18731615 T DK 18731615T DK 3631017 T3 DK3631017 T3 DK 3631017T3
Authority
DK
Denmark
Prior art keywords
melanom
detection
methods
melanom detection
Prior art date
Application number
DK18731615.3T
Other languages
Danish (da)
English (en)
Inventor
Irvin Modlin
Mark Kidd
Ignat Drozdov
Original Assignee
Liquid Biopsy Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Res Llc filed Critical Liquid Biopsy Res Llc
Application granted granted Critical
Publication of DK3631017T3 publication Critical patent/DK3631017T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
DK18731615.3T 2017-05-25 2018-05-21 Fremgangsmåder til melanompåvisning DK3631017T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511058P 2017-05-25 2017-05-25
PCT/US2018/033658 WO2018217627A1 (en) 2017-05-25 2018-05-21 Methods for melanoma detection

Publications (1)

Publication Number Publication Date
DK3631017T3 true DK3631017T3 (da) 2022-06-20

Family

ID=62620988

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18731615.3T DK3631017T3 (da) 2017-05-25 2018-05-21 Fremgangsmåder til melanompåvisning

Country Status (14)

Country Link
US (2) US20180340934A1 (https=)
EP (1) EP3631017B1 (https=)
JP (1) JP7227964B2 (https=)
KR (1) KR102763004B1 (https=)
CN (1) CN111315897B (https=)
AU (1) AU2018273844B2 (https=)
BR (1) BR112019024481A2 (https=)
CA (1) CA3064732A1 (https=)
DK (1) DK3631017T3 (https=)
ES (1) ES2920288T3 (https=)
IL (1) IL270787B2 (https=)
MX (1) MX2019014026A (https=)
PL (1) PL3631017T3 (https=)
WO (1) WO2018217627A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102763004B1 (ko) 2017-05-25 2025-02-04 리퀴드 바이옵시 리서치 엘엘씨 흑색종의 검출 방법
MX2022004372A (es) 2019-10-10 2022-07-27 Liquid Biopsy Res Llc Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838732A4 (en) * 2005-01-07 2010-07-14 Univ Johns Hopkins BIOMARKER FOR MELANOME
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
AU2007347118B2 (en) * 2006-11-03 2012-11-01 Baylor Research Institute Diagnosis of metastatic melanoma and monitoring indicators of immunosuppression through blood leukocyte microarray analysis
US20100248225A1 (en) * 2006-11-06 2010-09-30 Bankaitis-Davis Danute M Gene expression profiling for identification, monitoring and treatment of melanoma
US20110070582A1 (en) 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
EP2488874A4 (en) * 2009-10-13 2013-08-14 Univ Johns Hopkins BIOMARKERS FOR THE IDENTIFICATION OF MELANOMOTUM CELLS
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
EA201590041A1 (ru) * 2012-07-03 2015-04-30 Ратиофарм Гмбх Твердая форма холиновой соли вемурафениба
EP3194618B1 (en) * 2014-09-15 2021-04-21 Clifton Life Sciences LLC Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
KR102763004B1 (ko) 2017-05-25 2025-02-04 리퀴드 바이옵시 리서치 엘엘씨 흑색종의 검출 방법

Also Published As

Publication number Publication date
EP3631017B1 (en) 2022-03-23
CN111315897A (zh) 2020-06-19
IL270787B2 (en) 2023-08-01
CN111315897B (zh) 2024-10-22
ES2920288T3 (es) 2022-08-02
US12399179B2 (en) 2025-08-26
JP2020524524A (ja) 2020-08-20
AU2018273844A1 (en) 2019-12-19
EP3631017A1 (en) 2020-04-08
JP7227964B2 (ja) 2023-02-22
CA3064732A1 (en) 2018-11-29
BR112019024481A2 (pt) 2020-07-14
MX2019014026A (es) 2020-08-03
US20230022236A1 (en) 2023-01-26
AU2018273844B2 (en) 2024-11-14
US20180340934A1 (en) 2018-11-29
KR102763004B1 (ko) 2025-02-04
WO2018217627A1 (en) 2018-11-29
KR20200030034A (ko) 2020-03-19
PL3631017T3 (pl) 2022-09-26
IL270787B1 (en) 2023-04-01
IL270787A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
EP3711826A4 (en) RECOGNITION SYSTEM
PL3739299T3 (pl) Wykrywanie obiektów
EP3408402A4 (en) MAGNETIC ELECTROCHEMICAL DETECTION
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
DK3538864T3 (da) Mikrotom
DK3346961T3 (da) Anordning til stomi
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3298718T3 (da) Teknikker til signal-forlængelsessignalering
DE112016000423T8 (de) Abschnittslinienerkennungsvorrichtung
DK3125898T3 (da) Farmakofor til trail-induktion
DK3314010T3 (da) Fremgangsmåde til detektering af kromosomaberrationer
DK3477274T3 (da) Lækagedetektering
EP3565457C0 (en) DETECTION DEVICE
FI20146115A7 (fi) Menetelmä kemikaalitestausta varten
EP2998732C0 (en) ANALYSIS PROCESS
DE112017004618T8 (de) Objekterfassungsvorrichtung
DK3606936T3 (da) Fremgangsmåde til indvinding
DK3511705T3 (da) Detekteringsanordning
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
EP3598129A4 (en) SAMPLE DETECTION SYSTEM
DK3589742T3 (da) Fremgangsmåde til detektering
IT201600092505A1 (it) Dispositivo di rilevazione di posizione
EP3610036A4 (en) DETECTION CASCADES
EP3552007A4 (en) GAS DETECTION TECHNIQUE
DK3748358T3 (da) Cellebaseret fremgangsmåde til bestemmelse af virkningsgraden af defibrotid